Menu Back toSpecial-Population-Study-Challenges

DIA 2018 Global Annual Meeting

Special Population Study Challenges

    Session Chair(s)
      William B. Smith, MD

      William B. Smith, MD

      • President
      • VRG/NOCCR, An AMR Company, United States
    Early phase pharmacokinetic studies continue to be challenging. Current issues from regulatory, CRO/Sponsor, and site perspectives will be discussed and suggestions for optimizing protocols and operations will be presented.
    Learning Objective : Describe the design challenges of special population studies; Develop practical solutions to special population study obstacles.
      Charu  Gautam, MD

      Critical Challenges in Conducting PK Studies in Patients and Special Populations

      Charu Gautam, MD

      • Head- Early Clinical Development, Asia Pacific
      • IQVIA, India
      Harry  Alcorn, PharmD

      Special Population Studies: Thirty Years Experience Shared

      Harry Alcorn, PharmD

      • Chief Scientific Officer
      • DaVita Clinical Research, United States